Tuberculosis that takes away lives of two million people remains a very dangerous disease. Physicians all over the world are working to produce efficient tuberculosis vaccines, but their effort has not succeeded yet. All preparations available do not ensure complete protection from the disease.
For example, efficiency of one of the most widespread vaccines – BCG – varies from 80% to 0%. The experimental vaccine, the Novosibirsk researchers are working at, is a DNA fragment that codes the ESAT-6 mycobacterial antigen. Production of such a vaccine became possible after thorough investigation of genomes of mycobacteria – causative agent of tuberculosis – and of a congener bacterium - Mycobacterium bovis.
The majority of existing tuberculosis vaccines represent weakened mycobacteria cultures: a vaccine is supposed to provoke the immune response, but not the disease. The bacteria are weakened by removing from them the genes that are responsible for virulent properties, including the gene that codes the ESAT-6. It is absent from all existing Mycobacterium bovis BCG vaccine cultures. The Novosibirsk researchers staked specifically on this protein, which should not pose danger by itself .
Having established a proper genetically engineered construction, the researchers surrounded it by a polysacharide covering of polyglucin and spermidine. The covering reliably protects the DNA from enzymes that can destroy it. In the organism, polyglucin gradually decomposes, and the DNA becomes accessible to the immune system cells. The mice were immunized by the obtained preparation for three times. The preparation was injected intramuscularly at a two-week interval. The reference group animals were immunized by polysaccharides and the DNA, which did not contain the vaccine gene.
After vaccination, the mice were observed for 10 more days, and during this period, they did not lose weight and did not show any other symptoms of health impairment. Nevertheless, the animals had to be slaughtered to investigate their immune system reaction. Vaccines should stimulate cell-mediated immunity, and indeed, lymphocyte clones were formed with mice after immunization. The lymphocyte clones started to divide actively in response to introduction of the real ESAT-6 protein, at that the reaction significantly exceeded the background reaction. As for the reference group mice, their lymphocytes did not react to the protein injection. The analysis has proved that specific cell-mediated immunity was formed with vaccinated mice.
This is not a vaccine yet, it is only the first step to its development. As a matter of fact, the step has been successful.
Olga Myznikova | alfa
Purdue cancer identity technology makes it easier to find a tumor's 'address'
16.11.2018 | Purdue University
Microgel powder fights infection and helps wounds heal
14.11.2018 | Michigan Technological University
Researchers at the University of New Hampshire have captured a difficult-to-view singular event involving "magnetic reconnection"--the process by which sparse particles and energy around Earth collide producing a quick but mighty explosion--in the Earth's magnetotail, the magnetic environment that trails behind the planet.
Magnetic reconnection has remained a bit of a mystery to scientists. They know it exists and have documented the effects that the energy explosions can...
Biochips have been developed at TU Wien (Vienna), on which tissue can be produced and examined. This allows supplying the tissue with different substances in a very controlled way.
Cultivating human cells in the Petri dish is not a big challenge today. Producing artificial tissue, however, permeated by fine blood vessels, is a much more...
Faster and secure data communication: This is the goal of a new joint project involving physicists from the University of Würzburg. The German Federal Ministry of Education and Research funds the project with 14.8 million euro.
In our digital world data security and secure communication are becoming more and more important. Quantum communication is a promising approach to achieve...
On Saturday, 10 November 2018, the research icebreaker Polarstern will leave its homeport of Bremerhaven, bound for Cape Town, South Africa.
When choosing materials to make something, trade-offs need to be made between a host of properties, such as thickness, stiffness and weight. Depending on the application in question, finding just the right balance is the difference between success and failure
Now, a team of Penn Engineers has demonstrated a new material they call "nanocardboard," an ultrathin equivalent of corrugated paper cardboard. A square...
09.11.2018 | Event News
06.11.2018 | Event News
23.10.2018 | Event News
16.11.2018 | Health and Medicine
16.11.2018 | Life Sciences
16.11.2018 | Life Sciences